%0 Journal Article
%A Gil-Gómez, Antonio
%A Rojas, Ángela
%A García-Lozano, María R
%A Muñoz-Hernández, Rocío
%A Gallego-Durán, Rocío
%A Maya-Miles, Douglas
%A Montero-Vallejo, Rocío
%A Gato, Sheila
%A Gallego, Javier
%A Francés, Rubén
%A Soriano, Germán
%A Ampuero, Javier
%A Romero-Gómez, Manuel
%T Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients.
%D 2022
%U http://hdl.handle.net/10668/21201
%X A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and cirrhosis. In this study, we aimed to evaluate the prognosis of cirrhotic patients harboring this variant. We performed a retrospective analysis on 483 prospectively recruited patients from four different hospitals in Spain, followed-up for at least 5 years. We collected clinical, demographic, and biochemical data, and we performed a genotyping analysis for common variants previously associated with liver disease risk (HSD17B13 rs72613567:TA and PNPLA3 rs738409). Patients homozygous for the TA allele showed a higher MELD score (p = 0.047), Child−Turcotte−Pugh score (p = 0.014), and INR levels (p = 0.046), as well as decreased albumin (p = 0.004) at baseline. After multivariate analysis, patients with the “protective” variant indeed had an increased risk of hepatic decompensation [aHR 2.37 (1.09−5.06); p = 0.029] and liver-related mortality [aHR 2.32 (1.20−4.46); p = 0.012]. Specifically, these patients had an increased risk of developing ascites (Log-R 11.6; p
%K HSD17B13
%K NAFLD
%K PNPLA3
%K SNP
%K ascites
%K cirrhosis
%K fibrosis
%K hepatic decompensation
%K hepatic encephalopathy
%K polymorphism
%~